Asia Green Biotechnology Corp. Announces Filing of Financial Statements on SEDAR
Asia Green Biotechnology Corp. Announces Filing of Financial Statements on SEDAR
[NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES]
[不得發佈至美國新聞線或傳播至美國境內]
CALGARY, AB / ACCESSWIRE / May 24, 2024 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") (CSE:ASIA) announces that, further to its news releases dated April 17, 2024, April 26, 2024, May 8, 2024, and May 10, 2024, the Company has filed the following continuous disclosure documents (collectively, the "Documents") on SEDAR:
加拿大亞洲綠色生物技術股份有限公司（"Asia Green"或"本公司"）(CSE:ASIA) 於2024年5月24日發佈公告，根據2024年4月17日， 4月26日， 5月8日和5月10日的發佈的新聞，本公司正在SEDAR上提交以下連續披露文件（統稱"文件"）:
- the Company's Annual Audited Financial Statements for the year ended December 31, 2023, as required by section 4.2 of National Instrument 51-102 - Continuous Disclosure Obligations ("NI 51-102"); and
- the Company's Management Discussion & Analysis for the year ended December 31, 2023, as required by section 5.1(2) of NI 51-102.
- CEO and CFO certificates relating to the Audited Annual Financial Statements, as required by NI 52-109.
- 本公司2023年12月31日本pipC 22-長季性披露責任（"NI 51-102"）規定要求的年度審計財務報表;
- 本公司2023年12月31日本管館討論和分析，根據NI 51-102的5.1(2)要求。
- 本公司根據NI 52-109的要求提交的與審計年度財務報表相關的CEO和CFO證書。
It is expected that the Management Cease Trade Order ("MCTO") issued by the Alberta Securities Commission ("ASC") on May 8, 2024, will now be lifted.
預計亞伯達省證券委員會（"ASC"）於2024年5月8日發佈的管理停止交易命令（"MCTO"）現已解除。
In addition, the Company also announced today that Vincent Ghazar has resigned from his positions as Chief Financial Officer and Director of the Company. Mr. Ghazar will remain with the Company as a consultant providing accountancy services in the near term.
此外，本公司今天還宣佈文森特·加扎爾已辭去其擔任首席財務官和董事的職務。 加扎爾先生將在短期內繼續擔任本公司提供會計服務的顧問。
For further information, contact:
Asia Green Biotechnology Corp.
David Pinkman (CEO)
T: 403 863-6034
E: david.pinkman@asiagreenbiotechnology.com
如需更多信息，請聯繫：
亞洲綠色生物技術股份有限公司。
大衛·平克曼 (CEO)
電話：403 863-6034
電子郵件：david.pinkman@asiagreenbiotechnology.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
TSX創業公司交易所及其監管服務提供方（該術語定義在TSX創業公司政策中）不對此發佈的充分性或準確性承擔任何責任。
SOURCE: Asia Green Biotechnology Corp.
資訊來源：亞洲綠色生物科技企業
譯文內容由第三人軟體翻譯。